Duloxetine HCL DR Capsules

Pre-Solicitation Posted

This opportunity was awarded. See the award notice from , or the latest solicitation from .

Solicitation number
SPE2D219R0052
Agency
Responses due
Not on record
Set-aside
No set-aside

Opportunity facts

Notice details come from SAM.gov. Updated .

About this opportunity

The Defense Logistics Agency Troop Support Medical plans to issue a solicitation for a national requirements contract for Duloxetine HCL DR capsules. The contract will be a firm-fixed price, requirements-type contract with a one-year base and four one-year options to provide Duloxetine HCL DR in various bottle counts and strengths for purchase by the Department of Defense, Department of Veterans Affairs, and Indian Health Service through DLA and VA prime vendor programs. Interested parties should contact the named contracting officer by September 2019 for any questions, as the solicitation is expected to be issued in September 2019.

There is no set-aside designation for this opportunity. The projected NAICS code is 325412, Pharmaceutical Preparation Manufacturing, and PSC code is 6505, Drugs (Pharmaceutical Preparations). The current contract holders were not named. Annual usage estimates will be provided in the solicitation schedule.

Notice text

4 versions

Update #4 · Latest ·

Correcting Duloxetine HCL DR to reflect capsules i/l/o tablets.  

The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Duloxetine HCL DR.  Procurement details follow.Duloxetine HCL DR Capsules 20MG-60 count bottles; 30MG-30 count bottles; 30MG-90 count bottles; 60MG-30 count bottles and 60MG-1,000 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs and Indian Health Service customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency.  

A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and FEDBIZOPS at https://www.fbo.gov. Interested parties should contact Phyllis Daraio (215-737-7941) (phyllis.daraio@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre solicitation or solicitation changes through this website. The current projected solicitation date is October, 2019.  DLA reserves the right to issue the solicitation before or after the projected solicitation date.

Update #3 ·

Correcting Duloxetine HCL DR to reflect capsules i/l/o tablets.  

The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Duloxetine HCL DR.  Procurement details follow.

Duloxetine HCL DR Capsules 20MG-60 count bottles; 30MG-30 count bottles; 30MG-90 count bottles; 60MG-30 count bottles and 60MG-1,000 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs and Indian Health Service customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency.  

A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and FEDBIZOPS at https://www.fbo.gov. Interested parties should contact Phyllis Daraio (215-737-7941) (phyllis.daraio@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre solicitation or solicitation changes through this website. The current projected solicitation date is October, 2019.  DLA reserves the right to issue the solicitation before or after the projected solicitation date.

 

Update #2 ·

The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Duloxetine HCL DR.  Procurement details follow.

Duloxetine HCL DR Tablets 20MG-60 count bottles; 30MG-30 count bottles; 30MG-90 count bottles; 60MG-30 count bottles and 60MG-1,000 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs and Indian Health Service customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency.  

A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and FEDBIZOPS at https://www.fbo.gov. Interested parties should contact Phyllis Daraio (215-737-7941) (phyllis.daraio@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre solicitation or solicitation changes through this website. The current projected solicitation date is October, 2019.  DLA reserves the right to issue the solicitation before or after the projected solicitation date.

 

Update #1 ·

The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Duloxetine HCL DR.  Procurement details follow.

Duloxetine HCL DR Tablets 20MG-60 count bottles; 30MG-30 count bottles; 30MG-90 count bottles; 60MG-30 count bottles and 60MG-1,000 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs and Indian Health Service customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency.  

A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and FEDBIZOPS at https://www.fbo.gov. Interested parties should contact Phyllis Daraio (215-737-7941) (phyllis.daraio@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre solicitation or solicitation changes through this website. The current projected solicitation date is September, 2019.  DLA reserves the right to issue the solicitation before or after the projected solicitation date.

 

Notice history

Notice Type Posted
Duloxetine HCL DR Capsules Award Award Notice
Duloxetine HCL DR Capsules Latest solicitation Solicitation
This notice Original Pre-Solicitation

Similar open opportunities

Opportunity Agency Set-aside Responses due
Docusate sodium capsu Medical Supply Chain No set-aside
Citalopram hydrobromi Medical Supply Chain No set-aside
Fluconazole tablets Medical Supply Chain No set-aside
Trazodone tablets Medical Supply Chain No set-aside
Epinephrine Injector NAICS 325412 Medical Supply Chain No set-aside

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors